Beyond Injections: The Rise of Oral GLP-1 Therapy

The treatment landscape for obesity continues to evolve rapidly, and the approval of oral semaglutide (Ozempic; Novo Nordisk) for chronic weight management marks a significant milestone in obesity care. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has already transformed the management of type 2 diabetes and obesity through injectable formulations such as Ozempic and Wegovy. The introduction of an oral formulation offers a non-injectable alternative that may improve patient acceptance, adherence, and access to treatment. Recent clinical data from the OASIS program demonstrated substantial weight reduction with oral semaglutide, supporting its role as an effective therapeutic option for adults living with obesity.^1-3

Mechanism of Action

Semaglutide is a GLP-1 receptor agonist that mimics endogenous incretin hormones involved in appetite regulation and glucose homeostasis. Activation of GLP-1 receptors enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and increases satiety, ultimately leading to reduced caloric intake and weight loss. Like injectable semaglutide, the oral formulation utilizes sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that facilitates gastrointestinal uptake of the peptide.¹

Clinical Evidence Supporting Oral Semaglutide

The pivotal OASIS 1 trial (NCT05132088) evaluated oral semaglutide 50 mg once daily in adults with overweight or obesity without diabetes. Participants receiving oral semaglutide achieved a mean body weight reduction of approximately 15% from baseline after 68 weeks, compared with approximately 2% in the placebo group. Additionally, a greater proportion of participants achieved clinically meaningful weight loss thresholds of 5%, 10%, 15%, and 20% compared with placebo.¹

More recently, the OASIS 4 trial (NCT05564117) evaluated a lower-dose oral semaglutide regimen (25 mg daily) in adults with overweight or obesity. Results demonstrated significant weight reduction compared with placebo, further supporting the efficacy of oral semaglutide while potentially offering a dose that may be more practical for widespread clinical use.^2,3 Beyond weight loss, improvements in cardiometabolic risk factors—including waist circumference, blood pressure, lipid parameters, and glycemic measures—were observed in participants receiving treatment.¹

Advantages of an Oral Option

Although injectable GLP-1 receptor agonists have demonstrated impressive efficacy, some patients remain hesitant to initiate therapy due to needle aversion, injection burden, or concerns regarding administration technique. An oral formulation may help address these barriers and expand treatment accessibility.

Potential advantages include:

• Elimination of weekly injections
• Increased patient acceptance among injection-averse individuals
• Earlier initiation of obesity treatment
• Greater flexibility for patients preferring oral medications
• Potential expansion of obesity treatment uptake in primary care settings

The availability of an oral option may also help pharmacists engage more patients in discussions surrounding obesity management and adherence strategies.

Considerations for Pharmacists

Despite its convenience, oral semaglutide requires specific administration instructions to optimize absorption. Like oral semaglutide used for diabetes management, patients should take the medication on an empty stomach with a small amount of water and avoid food, beverages, and other medications for a specified period afterward. Failure to follow administration requirements may reduce drug absorption and efficacy.¹

Pharmacists should counsel patients regarding the following:

1. Proper administration timing
2. Gastrointestinal adverse effects such as nausea, vomiting, diarrhea, and constipation
3. Gradual dose escalation to improve tolerability
4. Recognition of symptoms of pancreatitis and gallbladder disease
5. The boxed warning regarding the potential risk of thyroid C-cell tumors

As with other GLP-1 receptor agonists, oral semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.³

Future Implications

The approval of oral semaglutide represents an important advancement in obesity pharmacotherapy and signals a broader shift toward oral peptide-based therapies. As competition in the obesity treatment market continues to grow, oral formulations may increase treatment accessibility and encourage earlier intervention in patients with obesity and obesity-related comorbidities. For pharmacists, the emergence of oral GLP-1 therapies reinforces the profession's role in medication counseling, adherence support, and evidence-based obesity management. As utilization expands, pharmacists will remain critical members of the interdisciplinary team helping patients navigate these novel treatment options and achieve long-term health outcomes.

REFERENCES

1. Knop FK, Aroda VR, Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719. doi:10.1016/S0140-6736(23)01185-6

2. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969

3. Novo Nordisk A/S: Wegovy pill approved in the US as first oral GLP-1 for weight management. News release. Novo Nordisk. December 22, 2025. Accessed June 23, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472

4. Satija B, Das K. EMA backs Novo’s Wegovy pill, first oral weight-loss drug for Europe. Reuters. May 22, 2026. Accessed June 23, 2026. https://www.reuters.com/legal/litigation/european-medicines-regulator-recommends-approval-novos-wegovy-pill-2026-05-22/